Title |
Amisulpride versus other atypical antipsychotics for schizophrenia
|
---|---|
Published in |
Cochrane database of systematic reviews, January 2010
|
DOI | 10.1002/14651858.cd006624.pub2 |
Pubmed ID | |
Authors |
Katja Komossa, Christine Rummel‐Kluge, Heike Hunger, Franziska Schmid, Sandra Schwarz, Joaquim I Silveira da Mota Neto, Werner Kissling, Stefan Leucht |
Abstract |
In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of amisulpride differs from that of other second generation antipsychotics. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 40% |
India | 1 | 20% |
Unknown | 2 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 140 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Chile | 1 | <1% |
Germany | 1 | <1% |
Brazil | 1 | <1% |
Unknown | 137 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 22 | 16% |
Student > Master | 19 | 14% |
Student > Bachelor | 15 | 11% |
Student > Doctoral Student | 12 | 9% |
Student > Ph. D. Student | 12 | 9% |
Other | 25 | 18% |
Unknown | 35 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 49 | 35% |
Psychology | 18 | 13% |
Nursing and Health Professions | 11 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
Agricultural and Biological Sciences | 5 | 4% |
Other | 11 | 8% |
Unknown | 40 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2022.
All research outputs
#2,799,234
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#5,432
of 11,499 outputs
Outputs of similar age
#13,609
of 172,589 outputs
Outputs of similar age from Cochrane database of systematic reviews
#32
of 115 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,589 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 115 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.